254 related articles for article (PubMed ID: 23055747)
1. Denosumab: a new option in the treatment of bone metastases from urological cancers.
Yuasa T; Yamamoto S; Urakami S; Fukui I; Yonese J
Onco Targets Ther; 2012; 5():221-9. PubMed ID: 23055747
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis.
Jakob T; Tesfamariam YM; Macherey S; Kuhr K; Adams A; Monsef I; Heidenreich A; Skoetz N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013020. PubMed ID: 33270906
[TBL] [Abstract][Full Text] [Related]
3. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
Fizazi K; Carducci M; Smith M; Damião R; Brown J; Karsh L; Milecki P; Shore N; Rader M; Wang H; Jiang Q; Tadros S; Dansey R; Goessl C
Lancet; 2011 Mar; 377(9768):813-22. PubMed ID: 21353695
[TBL] [Abstract][Full Text] [Related]
4. A comprehensive review of denosumab for bone metastasis in patients with solid tumors.
Gül G; Sendur MA; Aksoy S; Sever AR; Altundag K
Curr Med Res Opin; 2016; 32(1):133-45. PubMed ID: 26451465
[TBL] [Abstract][Full Text] [Related]
5. Effects of RANKL-Targeted Therapy in Immunity and Cancer.
Cheng ML; Fong L
Front Oncol; 2014 Jan; 3():329. PubMed ID: 24432249
[TBL] [Abstract][Full Text] [Related]
6. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study.
Stopeck AT; Lipton A; Body JJ; Steger GG; Tonkin K; de Boer RH; Lichinitser M; Fujiwara Y; Yardley DA; Viniegra M; Fan M; Jiang Q; Dansey R; Jun S; Braun A
J Clin Oncol; 2010 Dec; 28(35):5132-9. PubMed ID: 21060033
[TBL] [Abstract][Full Text] [Related]
7. [The treatment for cancer with bone metastases -whether to use zoledoronate or denosumab for bone metastases-].
Kohno N
Clin Calcium; 2014 Aug; 24(8):1229-36. PubMed ID: 25065876
[TBL] [Abstract][Full Text] [Related]
8. Denosumab for the prevention of skeletal-related events in patients with bone metastasis from solid tumor.
Iranikhah M; Wilborn TW; Wensel TM; Ferrell JB
Pharmacotherapy; 2012 Mar; 32(3):274-84. PubMed ID: 22392458
[TBL] [Abstract][Full Text] [Related]
9. Skeletal and extraskeletal actions of denosumab.
Sinningen K; Tsourdi E; Rauner M; Rachner TD; Hamann C; Hofbauer LC
Endocrine; 2012 Aug; 42(1):52-62. PubMed ID: 22581255
[TBL] [Abstract][Full Text] [Related]
10. Management of bone metastases in refractory prostate cancer--role of denosumab.
Paller CJ; Carducci MA; Philips GK
Clin Interv Aging; 2012; 7():363-72. PubMed ID: 23049248
[TBL] [Abstract][Full Text] [Related]
11. Role of denosumab in the management of skeletal complications in patients with bone metastases from solid tumors.
Brown-Glaberman U; Stopeck AT
Biologics; 2012; 6():89-99. PubMed ID: 22532777
[TBL] [Abstract][Full Text] [Related]
12. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
[TBL] [Abstract][Full Text] [Related]
13. [Anti-RANKL antibody for the management of bone metastasis].
Yoneda T
Gan To Kagaku Ryoho; 2011 Sep; 38(9):1439-45. PubMed ID: 21918338
[TBL] [Abstract][Full Text] [Related]
14. Bone-targeted agents and skeletal-related events in breast cancer patients with bone metastases: the state of the art.
Clemons M; Gelmon KA; Pritchard KI; Paterson AH
Curr Oncol; 2012 Oct; 19(5):259-68. PubMed ID: 23144574
[TBL] [Abstract][Full Text] [Related]
15. Denosumab: A comprehensive review.
Narayanan P
South Asian J Cancer; 2013 Oct; 2(4):272-7. PubMed ID: 24455656
[TBL] [Abstract][Full Text] [Related]
16. The RANK-RANKL-OPG System: A Multifaceted Regulator of Homeostasis, Immunity, and Cancer.
De Leon-Oliva D; Barrena-Blázquez S; Jiménez-Álvarez L; Fraile-Martinez O; García-Montero C; López-González L; Torres-Carranza D; García-Puente LM; Carranza ST; Álvarez-Mon MÁ; Álvarez-Mon M; Diaz R; Ortega MA
Medicina (Kaunas); 2023 Sep; 59(10):. PubMed ID: 37893470
[TBL] [Abstract][Full Text] [Related]
17. Targeting RANKL in metastasis.
Dougall WC; Holen I; González Suárez E
Bonekey Rep; 2014; 3():519. PubMed ID: 24795813
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; Sleeboom H; Spencer A; Vadhan-Raj S; von Moos R; Willenbacher W; Woll PJ; Wang J; Jiang Q; Jun S; Dansey R; Yeh H
J Clin Oncol; 2011 Mar; 29(9):1125-32. PubMed ID: 21343556
[TBL] [Abstract][Full Text] [Related]
19. Quantitative pharmacology of denosumab in patients with bone metastases from solid tumors.
Perez Ruixo JJ; Doshi S; Sohn W; Chow A
J Clin Pharmacol; 2015 Mar; 55 Suppl 3():S85-92. PubMed ID: 25707967
[TBL] [Abstract][Full Text] [Related]
20. Denosumab for the treatment of bone metastases in advanced breast cancer.
Casas A; Llombart A; Martín M
Breast; 2013 Oct; 22(5):585-92. PubMed ID: 23759273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
